Literature DB >> 28252822

Diagnostic performance between contrast enhancement, proton MR spectroscopy, and amide proton transfer imaging in patients with brain tumors.

Akihiko Sakata1, Yasutaka Fushimi1, Tomohisa Okada2, Yoshiki Arakawa3, Takeharu Kunieda3, Sachiko Minamiguchi4, Aki Kido1, Naotaka Sakashita5, Susumu Miyamoto3, Kaori Togashi1.   

Abstract

PURPOSE: To explore the relationship among parameters of magnetic resonance spectroscopy (MRS) and amide proton transfer (APT) imaging, and to assess the diagnostic performance of MRS and APT imaging for grading brain tumors in comparison with contrast enhancement of conventional MRI for preoperative grading in patients with brain tumor.
MATERIALS AND METHODS: Institutional Review Board approval and written informed consent were obtained. Forty-one patients with suspected brain tumors were enrolled in the study. Single-voxel MRS and 2D APT imaging of the same slice level were conducted using a 3T MRI scanner. Positive or negative contrast enhancement on T1 -weighted images was assessed by two neuroradiologists. Correlations among metabolite concentrations, metabolite ratios, and calculated histogram parameters, including mean APT (APTmean ) and the 90th percentile of APT (APT90 ) were assessed using Spearman's correlation coefficient. Diagnostic performance was evaluated with receiver operating characteristic (ROC) curve analysis for contrast enhancement and MRS and APT imaging. Values of P < 0.05 were considered statistically significant.
RESULTS: Positive correlations with statistical significance were found between total concentration of choline (Cho) and APT90 (r = 0.49), and between Cho/creatine (Cr) and APTmean (r = 0.65) as well as APT90 (r = 0.49). A negative correlation with statistical significance was observed between NAA/Cr and APTmean (r = -0.52). According to ROC curves, Cho/Cr, APTmean , APT90 , demonstrated higher area under the curve (AUC) values than that of contrast enhancement in grading gliomas.
CONCLUSION: Significant correlations were observed between metabolite concentrations and ratios on MRS and APT values. MRS and APT imaging showed comparable diagnostic capability for grading brain tumors, suggesting that both MRS and APT imaging offer potential for quantitatively assessing similar biological characteristics in brain tumors on noncontrast MRI. LEVEL OF EVIDENCE: 2 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;46:732-739.
© 2017 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  amide proton transfer imaging; chemical exchange saturation transfer; magnetic resonance imaging; magnetic resonance spectroscopy

Mesh:

Substances:

Year:  2017        PMID: 28252822     DOI: 10.1002/jmri.25597

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  13 in total

Review 1.  Amide proton transfer imaging of tumors: theory, clinical applications, pitfalls, and future directions.

Authors:  Kiyohisa Kamimura; Masanori Nakajo; Tomohide Yoneyama; Koji Takumi; Yuichi Kumagae; Yoshihiko Fukukura; Takashi Yoshiura
Journal:  Jpn J Radiol       Date:  2018-10-19       Impact factor: 2.374

Review 2.  The Applicability of Amide Proton Transfer Imaging in the Nervous System: Focus on Hypoxic-Ischemic Encephalopathy in the Neonate.

Authors:  Yang Zheng; Xiaoming Wang
Journal:  Cell Mol Neurobiol       Date:  2017-09-23       Impact factor: 5.046

3.  Endogenous Chemical Exchange Saturation Transfer MRI for the Diagnosis and Therapy Response Assessment of Brain Tumors: A Systematic Review.

Authors:  Sachi Okuchi; Ahmed Hammam; Xavier Golay; Mina Kim; Stefanie Thust
Journal:  Radiol Imaging Cancer       Date:  2020-01-31

Review 4.  Neuroimaging at 7 Tesla: a pictorial narrative review.

Authors:  Tomohisa Okada; Koji Fujimoto; Yasutaka Fushimi; Thai Akasaka; Dinh H D Thuy; Atsushi Shima; Nobukatsu Sawamoto; Naoya Oishi; Zhilin Zhang; Takeshi Funaki; Yuji Nakamoto; Toshiya Murai; Susumu Miyamoto; Ryosuke Takahashi; Tadashi Isa
Journal:  Quant Imaging Med Surg       Date:  2022-06

Review 5.  Application of 7T MRS to High-Grade Gliomas.

Authors:  L McCarthy; G Verma; G Hangel; A Neal; B A Moffat; J P Stockmann; O C Andronesi; P Balchandani; C G Hadjipanayis
Journal:  AJNR Am J Neuroradiol       Date:  2022-05-26       Impact factor: 4.966

6.  Amide proton transfer-weighted MRI in distinguishing high- and low-grade gliomas: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Ji Eun Park; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim; Ho Sung Kim
Journal:  Neuroradiology       Date:  2019-01-21       Impact factor: 2.804

7.  Amid proton transfer (APT) and magnetization transfer (MT) MRI contrasts provide complimentary assessment of brain tumors similarly to proton magnetic resonance spectroscopy imaging (MRSI).

Authors:  Changliang Su; Lingyun Zhao; Shihui Li; Jingjing Jiang; Kejia Cai; Jingjing Shi; Yihao Yao; Qilin Ao; Guiling Zhang; Nanxi Shen; Shan Hu; Jiaxuan Zhang; Yuanyuan Qin; Wenzhen Zhu
Journal:  Eur Radiol       Date:  2018-08-13       Impact factor: 5.315

8.  Hybrid MR-PET of brain tumours using amino acid PET and chemical exchange saturation transfer MRI.

Authors:  N A da Silva; P Lohmann; J Fairney; A W Magill; A-M Oros Peusquens; C-H Choi; R Stirnberg; G Stoffels; N Galldiks; X Golay; K-J Langen; N Jon Shah
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-24       Impact factor: 9.236

9.  CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.

Authors:  Laura Mancini; Stefano Casagranda; Guillaume Gautier; Philippe Peter; Bruno Lopez; Lewis Thorne; Andrew McEvoy; Anna Miserocchi; George Samandouras; Neil Kitchen; Sebastian Brandner; Enrico De Vita; Francisco Torrealdea; Marilena Rega; Benjamin Schmitt; Patrick Liebig; Eser Sanverdi; Xavier Golay; Sotirios Bisdas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-14       Impact factor: 10.057

10.  Correlation between amide proton transfer-related signal intensity and diffusion and perfusion magnetic resonance imaging parameters in high-grade glioma.

Authors:  Masanori Nakajo; Manisha Bohara; Kiyohisa Kamimura; Nayuta Higa; Takashi Yoshiura
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.